Blood Loss and Visibility with Esmolol vs Labetalol in Endoscopic Sinus Surgery: A Randomized Clinical Trial.

Philip F LavereNikunj A RanaMichael P KinskyJ Sean FunstonSharif S MohamedMohamad R Chaaban

Published in: Clinical medicine insights. Ear, nose and throat (2019)

There were no significant differences between esmolol and labetalol in rate of blood loss, MAP control, HR, or surgical visibility in FESS. Either drug may be used, and other considerations (availability, cost) can dictate choice.

Keyphrases

minimally invasive
coronary artery bypass
ultrasound guided
surgical site infection
decision making
percutaneous coronary intervention
acute coronary syndrome
endoscopic submucosal dissection